OPKO Health Reports $124.2 Million Revenue in Q1 2026, 17% Decrease Year-Over-Year

OPKO Health, Inc. reported a total revenue of $124.2 million for the first quarter of 2026, a decrease of 17% compared to $150.0 million in the same period of 2025. The decline was primarily driven by a significant drop in revenue from services, which fell by 30% to $72.2 million, largely due to the divestiture of BioReference's oncology diagnostics business to Labcorp in September 2025. In contrast, revenue from products increased by 9% to $38.0 million, and revenue from the transfer of intellectual property rose by 14% to $14.0 million, reflecting higher royalty income from NGENLA® and collaboration revenue.

The company's total costs and expenses decreased by 19% to $175.2 million, down from $217.1 million in the prior year. This reduction was attributed to lower costs associated with the divested operations and a decrease in clinical activity costs. As a result, OPKO's operating loss improved to $51.0 million, compared to a loss of $67.2 million in the first quarter of 2025. The net loss for the quarter was $54.8 million, or $0.07 per share, an improvement from a net loss of $67.6 million, or $0.10 per share, in the previous year.

In terms of strategic developments, OPKO has continued to expand its pharmaceutical pipeline, particularly through its subsidiary ModeX Therapeutics, which focuses on developing innovative immune therapies. The company has also entered into a collaboration agreement with Regeneron Pharmaceuticals to develop multispecific antibodies, which could yield significant future revenue. Additionally, OPKO's partnership with Pfizer for the commercialization of NGENLA® has secured regulatory approvals in over 50 markets, enhancing its market presence.

Operationally, OPKO's diagnostics segment has seen a shift in focus following the divestiture of its oncology business, concentrating on core clinical and women's health testing operations. The company reported a decrease in clinical test volumes and reimbursement rates, which contributed to the decline in service revenue. As of March 31, 2026, OPKO had cash, cash equivalents, and restricted cash totaling approximately $355.6 million, which the company believes is sufficient to meet its anticipated cash requirements for operations and debt service beyond the next 12 months.

Looking ahead, OPKO remains focused on advancing its pharmaceutical and diagnostic product pipelines while managing its operational costs. The company is also monitoring the impact of recent changes in U.S. trade policies and tariffs on its international operations. With ongoing collaborations and a strong cash position, OPKO aims to navigate the challenges in the healthcare market and capitalize on growth opportunities in its core business segments.